Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays.
Foot-and-mouth disease (FMD) affects economically important livestock and is one of the most contagious viral diseases. The most commonly used FMD diagnostic assay is a sandwich ELISA. However, the main disadvantage of this ELISA is that it requires anti-FMD virus (FMDV) serotype-specific antibodies...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6095514?pdf=render |
id |
doaj-af497286ece043398ed1c76b8d22136a |
---|---|
record_format |
Article |
spelling |
doaj-af497286ece043398ed1c76b8d22136a2020-11-25T01:57:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01138e020185310.1371/journal.pone.0201853Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays.Gareth ShimmonAbhay KotechaJingshan RenAmin S AsforJoseph NewmanStephen BerrymanEleanor M CottamSarah GoldToby J TuthillDonald P KingEmiliana BrocchiAndrew M Q KingRay OwensElizabeth E FryDavid I StuartAlison BurmanTerry JacksonFoot-and-mouth disease (FMD) affects economically important livestock and is one of the most contagious viral diseases. The most commonly used FMD diagnostic assay is a sandwich ELISA. However, the main disadvantage of this ELISA is that it requires anti-FMD virus (FMDV) serotype-specific antibodies raised in small animals. This problem can be, in part, overcome by using anti-FMDV monoclonal antibodies (MAbs) as detecting reagents. However, the long-term use of MAbs may be problematic and they may need to be replaced. Here we have constructed chimeric antibodies (mouse/rabbit D9) and Fabs (fragment antigen-binding) (mouse/cattle D9) using the Fv (fragment variable) regions of a mouse MAb, D9 (MAb D9), which recognises type O FMDV. The mouse/rabbit D9 chimeric antibody retained the FMDV serotype-specificity of MAb D9 and performed well in a FMDV detection ELISA as well as in routine laboratory assays. Cryo-electron microscopy analysis confirmed engagement with antigenic site 1 and peptide competition studies identified the aspartic acid at residue VP1 147 as a novel component of the D9 epitope. This chimeric expression approach is a simple but effective way to preserve valuable FMDV antibodies, and has the potential for unlimited generation of antibodies and antibody fragments in recombinant systems with the concomitant positive impacts on the 3Rs (Replacement, Reduction and Refinement) principles.http://europepmc.org/articles/PMC6095514?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gareth Shimmon Abhay Kotecha Jingshan Ren Amin S Asfor Joseph Newman Stephen Berryman Eleanor M Cottam Sarah Gold Toby J Tuthill Donald P King Emiliana Brocchi Andrew M Q King Ray Owens Elizabeth E Fry David I Stuart Alison Burman Terry Jackson |
spellingShingle |
Gareth Shimmon Abhay Kotecha Jingshan Ren Amin S Asfor Joseph Newman Stephen Berryman Eleanor M Cottam Sarah Gold Toby J Tuthill Donald P King Emiliana Brocchi Andrew M Q King Ray Owens Elizabeth E Fry David I Stuart Alison Burman Terry Jackson Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays. PLoS ONE |
author_facet |
Gareth Shimmon Abhay Kotecha Jingshan Ren Amin S Asfor Joseph Newman Stephen Berryman Eleanor M Cottam Sarah Gold Toby J Tuthill Donald P King Emiliana Brocchi Andrew M Q King Ray Owens Elizabeth E Fry David I Stuart Alison Burman Terry Jackson |
author_sort |
Gareth Shimmon |
title |
Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays. |
title_short |
Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays. |
title_full |
Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays. |
title_fullStr |
Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays. |
title_full_unstemmed |
Generation and characterisation of recombinant FMDV antibodies: Applications for advancing diagnostic and laboratory assays. |
title_sort |
generation and characterisation of recombinant fmdv antibodies: applications for advancing diagnostic and laboratory assays. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2018-01-01 |
description |
Foot-and-mouth disease (FMD) affects economically important livestock and is one of the most contagious viral diseases. The most commonly used FMD diagnostic assay is a sandwich ELISA. However, the main disadvantage of this ELISA is that it requires anti-FMD virus (FMDV) serotype-specific antibodies raised in small animals. This problem can be, in part, overcome by using anti-FMDV monoclonal antibodies (MAbs) as detecting reagents. However, the long-term use of MAbs may be problematic and they may need to be replaced. Here we have constructed chimeric antibodies (mouse/rabbit D9) and Fabs (fragment antigen-binding) (mouse/cattle D9) using the Fv (fragment variable) regions of a mouse MAb, D9 (MAb D9), which recognises type O FMDV. The mouse/rabbit D9 chimeric antibody retained the FMDV serotype-specificity of MAb D9 and performed well in a FMDV detection ELISA as well as in routine laboratory assays. Cryo-electron microscopy analysis confirmed engagement with antigenic site 1 and peptide competition studies identified the aspartic acid at residue VP1 147 as a novel component of the D9 epitope. This chimeric expression approach is a simple but effective way to preserve valuable FMDV antibodies, and has the potential for unlimited generation of antibodies and antibody fragments in recombinant systems with the concomitant positive impacts on the 3Rs (Replacement, Reduction and Refinement) principles. |
url |
http://europepmc.org/articles/PMC6095514?pdf=render |
work_keys_str_mv |
AT garethshimmon generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT abhaykotecha generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT jingshanren generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT aminsasfor generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT josephnewman generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT stephenberryman generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT eleanormcottam generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT sarahgold generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT tobyjtuthill generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT donaldpking generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT emilianabrocchi generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT andrewmqking generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT rayowens generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT elizabethefry generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT davidistuart generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT alisonburman generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays AT terryjackson generationandcharacterisationofrecombinantfmdvantibodiesapplicationsforadvancingdiagnosticandlaboratoryassays |
_version_ |
1724973906233655296 |